Welcome to our dedicated page for Aeterna Zentaris news (Ticker: AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris stock.
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZS) is a global biopharmaceutical company specializing in endocrine therapy and oncology. With a robust track record in drug discovery, development, and commercialization, the company focuses on addressing significant unmet medical needs. Aeterna Zentaris' flagship product, macimorelin (marketed as Macrilen® in the U.S. and Ghryvelin™ in Europe), is the first and only FDA and European Commission-approved oral test for diagnosing adult growth hormone deficiency (AGHD). The company is actively pursuing the extension of macimorelin’s application for diagnosing childhood-onset growth hormone deficiency (CGHD), with the Phase 3 DETECT trial nearing completion.
Recently, Aeterna Zentaris announced a definitive agreement to merge with Ceapro Inc. The merger, expected to close in the second quarter of 2024, aims to leverage Ceapro's revenue-generating cosmeceutical and nutraceutical products, such as oat beta glucan and avenanthramides. The combined entity is poised to generate stable cash flow, diversify its product pipeline, enhance research and development capabilities, and strengthen its market presence in both North America and Europe.
The company remains committed to developing an array of therapeutic assets, including treatments for neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism, and amyotrophic lateral sclerosis (ALS). Aeterna Zentaris is well-capitalized, with a strategic plan to advance innovative products and deliver sustained value to its shareholders.
Aeterna Zentaris (NASDAQ: AEZS) has announced a share consolidation of its common shares, reducing approximately 121 million shares to around 4.9 million on a 1-for-25 basis, effective by July 21, 2022. This move aims to meet Nasdaq's minimum bid price requirement, crucial for the company's continued listing. Although Aeterna anticipates achieving compliance with the minimum bid price of $1.00 by August 3, 2022, it is expected to receive a notice of delisting shortly due to not meeting the ten-day trading requirement by July 25, 2022.
Aeterna Zentaris Inc. (NASDAQ: AEZS) has announced the approval of a Share Consolidation at a ratio of one post-consolidation share for every twenty-five pre-consolidation shares. This decision was made during the reconvened annual meeting of shareholders held on July 15, 2022. The company plans to file articles of amendment shortly, pending approval from the Toronto Stock Exchange and NASDAQ. Aeterna is known for its focus on developing pharmaceutical products and has achieved regulatory approval for its lead product, macimorelin, for adult growth hormone deficiency.
Aeterna Zentaris has further adjourned its annual general and special meeting originally scheduled for June 21, 2022, to provide additional time for shareholders to discuss the proposed Share Consolidation. This consolidation requires at least two-thirds approval and aims to prevent potential delisting from Nasdaq. The reconvened meeting is now set for July 15, 2022, at 10 a.m. ET. The record date for eligible voters remains May 17, 2022. Shareholders are encouraged to vote by 5:00 p.m. ET on July 14, 2022.
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that the vote on share consolidation was adjourned to July 6, 2022, while all other business items were approved at the recent shareholder meeting. The share consolidation, crucial for avoiding potential Nasdaq delisting, requires two-thirds approval. The meeting will reconvene virtually. Aeterna is also working with Kingsdale Advisors to gather proxy votes, and the record date for shareholder eligibility is May 17, 2022.
Aeterna Zentaris Inc. (NASDAQ: AEZS) has made strides in its AIM Biologicals program for treating neuromyelitis optica spectrum disorder (NMOSD), a severe autoimmune condition. Results presented at the 13th International Congress on Autoimmunity in Athens indicate that mouse-adapted AIM Biologicals may effectively reduce symptoms associated with NMOSD. The findings highlight the importance of AQP-4 antigen in treatment development, aiming to meet significant unmet medical needs among NMOSD patients.
Aeterna Zentaris (NASDAQ: AEZS) announces that Dr. Klaus Paulini, CEO, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 12:30 PM ET in New York. The presentation will focus on the company's portfolio of pharmaceutical and diagnostic products, including macimorelin, an approved oral test for diagnosing adult growth hormone deficiency. Management will also participate in one-on-one meetings with investors. A live video webcast will be available on the company's website and archived for 90 days.
Aeterna Zentaris (NASDAQ: AEZS) announces the European launch of Ghyrvelin™ (macimorelin), the first oral test for diagnosing Adult Growth Hormone Deficiency (AGHD). The product is available through their licensing partner, Consilient Health, marking a significant milestone for the company. Ghryvelin™ offers a well-tolerated, efficient alternative to traditional testing methods. The European approval came in 2019 based on Phase 3 data showing comparable accuracy to insulin tolerance testing, with a superior safety profile.
Aeterna Zentaris (NASDAQ: AEZS) announced that Dr. Klaus Paulini, CEO, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami and virtually. Following his presentation, management will be available for virtual one-on-one meetings with registered investors. A video webcast will be accessible for viewing starting May 24, 2022, at 7:00 AM ET for event registrants, and will remain available for 90 days. Aeterna is a specialty biopharma focusing on unmet medical needs, with products like macimorelin for diagnosing growth hormone deficiencies.
Aeterna Zentaris Inc. (NASDAQ: AEZS) has announced its Virtual Annual General Meeting (AGM) set for June 21, 2022, at 10:00 a.m. ET. Shareholders are urged to vote on a proposed share consolidation to remain compliant with Nasdaq’s listing standards, particularly the minimum bid price of US$1.00 for 10 consecutive days before July 26, 2022. Failure to comply could lead to delisting. The AGM will allow shareholders to vote and submit questions live. A detailed management information circular will precede the meeting.
Aeterna Zentaris (NASDAQ: AEZS) announced positive pre-clinical results for its Autoimmunity Modifying Biologicals (AIM Biologicals) aimed at treating Parkinson’s Disease (PD). Data presented at IMMUNOLOGY2022 demonstrated the immune-modulatory activity of HLA-G based molecules in various assays. The innovative approach focuses on inducing antigen-specific immunotolerance to combat neurodegeneration. The study results showed a trend towards improved motor function and neuron protection in animal models, suggesting substantial therapeutic potential for AIM Biologicals in PD.
FAQ
What is the current stock price of Aeterna Zentaris (AEZS)?
What is the market cap of Aeterna Zentaris (AEZS)?
What is Aeterna Zentaris Inc. focused on?
What is macimorelin?
What recent merger has Aeterna Zentaris announced?
What are some products offered by Ceapro?
What is the significance of the DETECT trial?
What therapeutic areas is Aeterna Zentaris developing products for?
What are the financial conditions of Aeterna Zentaris?
What strategic advantages will the merger with Ceapro bring?
What are the anticipated benefits of the combined company post-merger?
Where can I find more information about Aeterna Zentaris?
